Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) shares shot up 6.9% on Friday . The company traded as high as $1.84 and last traded at $1.69. 10,292 shares changed hands during trading, a decline of 64% from the average session volume of 28,922 shares. The stock had previously closed at $1.58.
Humacyte Stock Performance
The firm’s 50-day moving average is $1.84 and its 200-day moving average is $1.97.
Humacyte Company Profile
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Read More
- Five stocks we like better than Humacyte
- What is the S&P/TSX Index?
- Disney’s Magic Strategy: Reinventing the House of Mouse
- Why Are These Companies Considered Blue Chips?
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- What is a Dividend King?
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
